Last week, Amsterdam played host to this year’s edition of the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD).
For the 18th edition of this event, some of the biggest names in diabetes technology put their latest innovations on display. Updates for insulin delivery and glucose monitoring technologies dominated the headlines as many companies continue to advance their offerings.
News came from the likes of Dexcom, Medtronic, Insulet and Tandem Diabetes Care at this year’s ATTD event. Here are the biggest stories from this year’s ATTD conference in Florence, Italy.
(You can also check out our coverage of the biggest news out of ATTD in 2024, 2023 and 2022.)
Dexcom addresses type 2 diabetes, advances 15-day CGM and expands insulin delivery integrations
![The NovoPen Echo smart insulin pen now works with Dexcom CGM. [Image from Novo Nordisk]](https://www.drugdeliverybusiness.com/wp-content/uploads/2022/11/Novo-Nordisk-NovoPen-Echo-Smart-Insulin-Pen-Abbott-300x195.jpg)
One of the leaders in continuous glucose monitoring (CGM) technology, Dexcom, is enhancing its technologies while also attempting to raise awareness so that more people might use those technologies.
At ATTD, the company unveiled its “State of Type 2 Report: Access and Attitudes Across Europe and the Middle East.” This report surveyed 2,500 people with type 2 diabetes and healthcare professionals across Germany, Italy, the Netherlands, Saudi Arabia, Spain and the UK.
The findings delivered insights into care and perceptions of diabetes technology within the type 2 population. Dexcom COO Jake Leach explained Dexcom’s efforts on that front in an interview with Drug Delivery Business News.
Also at ATTD, Dexcom announced new insulin delivery integrations and updates on enhanced CGMs. First, the company announced that its G7 sensor directly connects with Novo Nordisk’s NovoPen 6 and NovoPen Echo Plus in Germany. Additionally, the company highlighted new data for its 15-day CGM, which delivered a mean absolute relative difference (MARD) of 8%. It says this improves upon the existing 10-day G7’s accuracy and will be the company’s most accurate CGM offering.
Tandem reports positive outcomes for insulin pumps in type 2 population
San Diego-based Tandem won FDA clearance for its Control-IQ+ next-generation algorithm for type 2 diabetes at the end of last month and, one day before ATTD started, the company announced the launch of the algorithm. Control-IQ+ represents the next generation of the company’s advanced hybrid closed-loop insulin delivery algorithm. It has compatibility with both the company’s pump offerings, the t:slim X2 and Mobi pumps.
Following the launch, Tandem offered further support for the algorithm with the presentation of data at ATTD supporting the system in the type 2 population.
The company’s 13-week study had a primary outcome of evaluating change in A1C with Control-IQ+ in adults 18 and older with type 2 diabetes. Additional outcomes included changes in CGM-measured time in range, time in hyperglycemia/hypoglycemia and safety events. Those include severe hypoglycemia, diabetic ketoacidosis and other serious adverse events.
Findings were published in the The New England Journal of Medicine (NEJM).
Results highlighted significant improvements in time in range and A1C in people with type 2 diabetes. The study compared users of Control-IQ+ technology to a control group that continued their pre-study insulin delivery method while using a CGM.
Insulet data supports switching from daily injections to Omnipod 5
At ATTD, Investigators shared data from the RADIANT study, a randomized controlled trial evaluating the direct transition from multiple daily injections (MDI) to automated insulin delivery (AID) with the Omnipod 5 system. Insulet says it marks the first study to do so — and is the first to assess the safety and efficacy of an AID system paired with the Abbott FreeStyle Libre 2 family sensor.
The study evaluated adults and children with type 1 diabetes not previously meeting clinical targets for HbA1c on MDI. It observed clinically significant improvements in HbA1c compared to MDI used with a CGM.
In addition to improving HbA1c, Omnipod 5 users spent an additional 5.4 hours per day in target glucose range compared to MDI. This resulted in a final time in range of 65%, up from 39% at baseline. The study also showed less time per day with high glucose levels and no increase in time spent with dangerously low glucose.
Insulet reported no life-threatening acute events involving severe hypoglycemia or diabetes-related ketoacidosis in either treatment group during the three-month study.
Medtronic reveals first real-world data on smart insulin pen system
The medtech giant made its mark at ATTD by sharing data evaluating its Smart MDI system, which combines the InPen with the Simplera CGM. Data showed how the system, designed for people with diabetes using multiple daily injections (MDI) when used as intended, helps users get closer to the internationally recommended 70% time in range (TIR) target.
Medtronic says it aims for its system to minimize the frequency of glucose highs for those on MDI. The Smart MDI system became the first on the market to recommend corrections for missed or inaccurate insulin doses last fall. The company received FDA approval for Simplera in August 2024 as well.
The company says its Smart MDI helps reduce guesswork and simplify diabetes management with real-time, personalized insights. Data showed that 52.6% of injections came after recommendations from the dose calculator.
Medtronic presently offers the Smart MDI system in 16 countries across Europe, the Middle East and Africa. It plans to initiate a limited rollout in the U.S., beginning with standalone CGM and InPen customers. Then it plans for a broad commercial launch.
Other noteworthy diabetes tech headlines that came up around ATTD
Some companies had announcements last week that weren’t necessarily related to ATTD, but are still worth noting. Here are a few:
